CGRP Inhibitors and Oxidative Stress Biomarkers in Resistant Migraine: A Real-Life Study with Erenumab, Fremanezumab, and Galcanezumab

Patients with high-frequency resistant migraine and medication-overuse headache are still the main clinical challenge in tertiary headache centers. The approval of targeted antibodies against the calcitonin gene-related peptide (CGRP) and its receptor represents a powerful instrument. In this study, we observed how biological and clinical features of resistant migraineurs responded to erenumab, fremanezumab, or galcanezumab. We found a reduction in advanced oxidation protein products (AOPP) as a biomarker of improved redox state after six months of treatment. We also found that treatment efficacy was precocious and maintained with high individual responder rates. In particular, seven out of ten patients achieved a reduction of 50% from the baseline at three months, which was maintained at six months, while about one out of our patients experienced a 75% reduction in headache frequency from the first month of treatment. The migraine disability assessment (MIDAS) and the associated fatigue, anxiety, and sleep quality also significantly improved. The allodynia symptom dropped from moderate/severe to mild/absent as a sign of central sensitization reduction. Our study confirmed the safety and efficacy of CGRP inhibition in real-life, high-challenging patients. Additional evidence is needed to understand the role of oxidative stress as a migraine biomarker.

[1]  M. Nowaczewska,et al.  Changes in Cerebral Blood Flow after Erenumab Treatment in Good and Non-Responders—A Pilot Study of Migraine Patients , 2021, Journal of clinical medicine.

[2]  E. Bellei,et al.  Urinary Proteomics Reveals Promising Biomarkers in Menstrually Related and Post-Menopause Migraine , 2021, Journal of clinical medicine.

[3]  S. Sacco,et al.  Social Distancing in Chronic Migraine during the COVID-19 Outbreak: Results from a Multicenter Observational Study , 2021, Nutrients.

[4]  Miguel A. Miranda,et al.  Burden and attitude to resistant and refractory migraine: a survey from the European Headache Federation with the endorsement of the European Migraine & Headache Alliance , 2021, The Journal of Headache and Pain.

[5]  E. Caronna,et al.  Update on Calcitonin Gene-Related Peptide Antagonism in the Treatment of Migraine. , 2021, Neurologic clinics.

[6]  S. Gori,et al.  Supersaturation of VEP in Migraine without Aura Patients Treated with Topiramate: An Anatomo-Functional Biomarker of the Disease , 2021, Journal of clinical medicine.

[7]  M. Zaletel,et al.  Enhanced Hemodynamic and Clinical Response to αCGRP in Migraine Patients—A TCD Study , 2021, Frontiers in Neurology.

[8]  F. Brighina,et al.  Migraine and Sport in a Physically Active Population of Students: Results of a Cross‐Sectional Study , 2020, Headache.

[9]  Eun Sug Park,et al.  Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019 , 2020, Lancet.

[10]  S. Sacco,et al.  European headache federation consensus on the definition of resistant and refractory migraine , 2020, The Journal of Headache and Pain.

[11]  C. D. Luca,et al.  The fifth cranial nerve in headaches , 2020, The Journal of Headache and Pain.

[12]  Sorana D. Bolboacă,et al.  Retinal Nerve Fiber Layer Thickness and Oxidative Stress Parameters in Migraine Patients without Aura: A Pilot Study , 2020, Antioxidants.

[13]  Lei Yang,et al.  Calcitonin gene‐related peptide inhibits angiotensin II‐induced NADPH oxidase‐dependent ROS via the Src/STAT3 signalling pathway , 2020, Journal of cellular and molecular medicine.

[14]  P. Ao,et al.  CGRP Reduces Apoptosis of DRG Cells Induced by High-Glucose Oxidative Stress Injury through PI3K/AKT Induction of Heme Oxygenase-1 and Nrf-2 Expression , 2019, Oxidative medicine and cellular longevity.

[15]  J. Schoenen,et al.  The metabolic face of migraine — from pathophysiology to treatment , 2019, Nature Reviews Neurology.

[16]  S. Gori,et al.  Plasma Levels of Oxidative Stress Markers, before and after BoNT/A Treatment, in Chronic Migraine , 2019, Toxins.

[17]  F. Guadagni,et al.  Circulating Biomarkers In Migraine. New Opportunities For Precision Medicine. , 2019, Current medicinal chemistry.

[18]  S. Taysı,et al.  Oxidative stress and DNA damage in patients with migraine , 2016, The Journal of Headache and Pain.

[19]  S. Gori,et al.  Evidences of Reduced Antioxidant Activity in Patients With Chronic Migraine and Medication‐Overuse Headache , 2015, Headache.

[20]  P. Martínez-Camblor,et al.  OnabotulinumtoxinA decreases interictal CGRP plasma levels in patients with chronic migraine , 2015, Pain.

[21]  S. Silberstein,et al.  Episodic and Chronic Migraine Headache: Breaking Down Barriers to Optimal Treatment and Prevention , 2015, Headache.

[22]  M. Aguggia Allodynia and migraine , 2012, Neurological Sciences.

[23]  L. Edvinsson Role of CGRP in Migraine. , 2019, Handbook of experimental pharmacology.

[24]  M. Arnold Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition , 2018, Cephalalgia : an international journal of headache.

[25]  S. Benemei,et al.  The TRPA1 channel in inflammatory and neuropathic pain and migraine. , 2014, Reviews of physiology, biochemistry and pharmacology.